MedPath

Impacts of Fermented Oat-based Product on Gut Microbiota and Health

Not Applicable
Completed
Conditions
Metabolic Syndrome
Interventions
Other: Fermented oat-based product
Other: Unfermented oat-based product
Registration Number
NCT06393114
Lead Sponsor
University of Eastern Finland
Brief Summary

This study aims to investigate the effects of consuming fermented oat-based products on gut and overall human health. It is a randomized, controlled, cross-over trial with a dietary intervention.

A total of 100 participants will be enrolled in this study and they will eat both fermented and unfermented oat-based products for three weeks. Participants will eat their habitual diet between the dietary intervention periods (wash-out).

During the study, participants' perceived health, inflammatory markers, glucose and lipid metabolism, tryptophan metabolites, gastrointestinal symptoms, and gut microbiota will be assessed.

Detailed Description

Plant-based protein sources, such as those derived from oats, are experiencing high demand due to their role in reducing reliance on animal products and promoting a more sustainable food system. Despite this, there is limited information available regarding the impact of components like fibre in plant-based foods on protein and other nutrients' metabolism.

Food fermentation emerges as a potential solution to enhance the absorption of plant-based protein and various nutrients in the small intestine. This is achieved by reducing antinutrients and facilitating the absorption process. Additionally, food fermentation has implications for the composition and metabolic activity of the gut microbiota, influencing metabolism, immune responses, intestinal function, and overall health. The metabolism of tryptophan in the gut, modulated by the gut microbiota and the production of various metabolites, may serve as a key link in these observed effects.

The fermentation of plant-based foods potentially enhances the beneficial health effects of these foods, and investigating this contributes to an increased understanding of the gut-mediated health effects of foods and the mechanisms behind them. This study will be part of a European research project HealthFerm.

Detailed objectives are to:

1. compare fermented and unfermented plant-based food products to blood lipid and glucose metabolism and gastrointestinal comfort as well as perceived and observed overall well-being.

2. study the effects of fermented and unfermented plant-based food consumption on the markers for gut permeability and inflammation.

3. study the difference in microbiota composition and diversity after consuming fermented and unfermented plant-based foods and its contribution to cardiometabolic outcomes.

4. study the difference in microbiota-related metabolites, especially tryptophan metabolites between fermented and unfermented plant-based foods.

A total of 100 participants will be enrolled in this randomized, controlled, cross-over trial, during which they will eat both fermented and unfermented oat-based products as part of their habitual diet. The study follows this sequence:

Weeks 1-3: Habitual diet Weeks 4-6: Dietary Intervention 1 Weeks 7-9: Habitual diet (wash-out) Weeks 10-12: Dietary Intervention 2

Blood, urinary and faecal samples, as well as food diaries and questionnaires, are collected at the end of each study period to assess participants' perceived health, inflammatory markers, glucose and lipid metabolism, tryptophan metabolites, gastrointestinal symptoms, and gut microbiota. In addition, participants' values and attitudes towards fermented foods are assessed. At the end of the study, participants will receive their laboratory results and dietary guidance for their habitual diet from a registered dietitian.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
57
Inclusion Criteria
  • Waist circumference >90 cm (women) or >100 cm (men) OR BMI 26-38 kg/m2

  • One of the following:

    • raised blood pressure (systolic ≥ 130 mmHg and/or diastolic 85 mmHg)
    • raised fasting plasma glucose (≥ 5.6 mmol/l)
    • raised triglycerides (≥ 1.7 mmol/l)
    • raised total cholesterol (≥ 5 mmol/l)
    • raised LDL (≥ 3 mmol/l)
    • reduced HDL (women < 1.3 mmol/l, men 1.0 mmol/l)
  • Use of cereal products and dairy products or their plant-based alternatives as a part of habitual diet

  • Willingness to follow intervention diets for the whole study

Exclusion Criteria
  • Diagnosed chronic diseases and conditions which could hamper the adherence to the dietary intervention protocol, e.g., chronic liver, thyroid, kidney, or gastrointestinal diseases
  • Pregnancy and lactation
  • Gluten-free or vegan diet
  • Recent use of antibiotics (within 3 months)
  • Gastrointestinal surgery (within 6 months)
  • Alcohol abuse (AUDIT ≥ 15 p and measures of liver function)
  • regular smoking or use of snus

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Fermented productFermented oat-based productParticipants will consume a fermented oat-based product daily for three weeks within their diet.
Unfermented productUnfermented oat-based productParticipants will consume an unfermented oat-based product daily for three weeks within their diet.
Primary Outcome Measures
NameTimeMethod
Inflammatory marker 1Weeks 3, 6, 9, and 12

P-hs-CRP (mg/l)

Inflammatory marker 3Weeks 3, 6, 9, and 12

LBP (μg/ml)

Inflammatory marker 2Weeks 3, 6, 9, and 12

IL-22

Secondary Outcome Measures
NameTimeMethod
Glucose metabolismWeeks 3, 6, 9, and 12

fP-Gluk and B-HbA1C (mmol/l)

Attitudes and valuesWeeks 0 and 12

Unvalidated questionnaire

Insulin responseWeeks 3, 6, 9, and 12

fP-Insu (mU/l)

Lipid metabolismWeeks 3, 6, 9, and 12

fP-Kol, fP-Kol-HDL, fP-Kol-LDL, fP-Trigly, and fP-FFA (mmol/l)

Self-reported overall healthWeeks 3, 6, 9, and 12

Short Form-36 Health Survey (SF-36). Different sections are rated from 0 to 100 points, where higher scores mean better perceived health.

Tryptophan metabolismWeeks 3, 6, 9, and 12

Tryptophan metabolites will be analysed with non-targeted metabolomics.

Changes in the composition gut microbiotaWeeks 3, 6, and 12

Composition of gut microbiota will be analysed from faecal samples

Self-reported mental healthWeeks 3, 6, 9, and 12

General Health Questionnaire-12 (GHQ-12). The questionnaire is rated from 0 to 12 points, where higher score means greater psychological distress.

Self-reported gut healthWeeks 3, 6, 9, and 12

Gastrointestinal Symptoms Rating Scale (GSRS)

Opinions about the study productsWeeks 6 and 12

Unvalidated questionnaire

Trial Locations

Locations (1)

University of Eastern Finland

🇫🇮

Kuopio, Finland

© Copyright 2025. All Rights Reserved by MedPath